Newfoundland Discovery Corp., a Canadian gold exploration company focused on Angola, has changed its name to Genesis Goldfields Corp. Along with the rebranding, its trading symbol on the Canadian Securities Exchange will change from NEWD to GGF starting October 6, 2026. The company continues to focus on its flagship Ganda Gold Project in Angola, aiming to develop a new gold district in a largely unexplored region. This change reflects the company's evolving identity and ongoing exploration efforts.
Newfoundland Discovery's name and ticker symbol change provide context for market watchers. For readers following Basic Materials, here is Pluang's market snapshot as of Oct 06, 2026 04:31 WIB: 24 of 38 priced US stocks rose and 14 fell. Agnico Eagle Mines Ltd traded at USD 181.18 with a 1-day change of -1.14%, and typical hold time on Pluang is 56 days.
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
